BEIGENE LTD
NASDAQ: BGNE (BeiGene, Ltd.)
Last update: 1 hour ago0.000
0.00 (0.00%)
| Price / Earnings (Forward) | 384.62 |
| Price / Sales | 6.06 |
| Price / Book | 5.96 |
| Profit Margin | -25.50% |
| Operating Margin (TTM) | -13.90% |
| Diluted EPS (TTM) | -8.18 |
| Quarterly Revenue Growth (YOY) | 39.50% |
| Total Debt/Equity (MRQ) | 30.54% |
| Current Ratio (MRQ) | 1.94 |
| Operating Cash Flow (TTM) | -4.56 B |
| Levered Free Cash Flow (TTM) | -5.26 B |
| Return on Assets (TTM) | -9.58% |
| Return on Equity (TTM) | -23.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BeiGene, Ltd. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.63 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene’s revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
| % Held by Insiders | 17.79% |
| % Held by Institutions | 44.98% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |